DNX Biopharmaceuticals
Irvine, California, United States
About DNX Biopharmaceuticals
DNX is a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases. Founded in 2014 and headquartered in Irvine, CA, USA, DNX is pursuing the development of new therapeutic proteins utilizing a 21st century, half-life extension platform technology known as PASylation, which is in-licensed from XL-protein GmbH. XLp has granted DNX a worldwide exclusive license under its patents and know-how related to the PASylation technology to develop and commercialize several PASylated products.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Last round: Non-Equity Assistance (May 2016)
- Website: dnxbio.com
- Phone: +1 (949) 224 3849
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/dnx-biopharmaceuticals-2519059 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.